Search

Your search keyword '"Y. Tandjaoui-Lambiotte"' showing total 3 results
Start Over Author "Y. Tandjaoui-Lambiotte" Publisher european respiratory society
3 results on '"Y. Tandjaoui-Lambiotte"'

1. Interstitial lung disease-related pneumomediastinum in COVID-19 patients.

Author

Blanc K, Bonnet N, Ouedraogo E, Arnaout M, Patout M, and Tandjaoui-Lambiotte Y

Abstract

Pneumomediastinum in severe #COVID19 presentations could be due to a lung parenchymal retractive process generated by intense inflammation as in acute exacerbation of idiopathic pulmonary fibrosis or MDA-5 acute interstitial lung disease https://bit.ly/3qzBYMW., Competing Interests: Conflict of interest: K. Blanc has nothing to disclose. Conflict of interest: N. Bonnet has nothing to disclose. Conflict of interest: E. Ouedraogo has nothing to disclose. Conflict of interest: M. Arnaout has nothing to disclose. Conflict of interest: M. Patout reports personal fees and nonfinancial support from Resmed, Philips Respironics and Asten, outside the submitted work. Conflict of interest: Y. Tandjaoui-Lambiotte has nothing to disclose., (Copyright ©The authors 2021.)

Published
2021
Full Text
View/download PDF

2. Impact of socioeconomic status in patients hospitalised for COVID-19 in the Greater Paris area.

Author

Sesé L, Nguyen Y, Giroux Leprieur E, Annesi-Maesano I, Cavalin C, Goupil de Bouillé J, Demestier L, Dhote R, Tandjaoui-Lambiotte Y, Bauvois A, Pépin M, Curac S, Beaune S, Duchemann B, and Nunes H

Subjects
Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Paris epidemiology, Prospective Studies, Severity of Illness Index, COVID-19 epidemiology, Hospitalization, Social Class
Abstract

Competing Interests: Conflict of interest: L. Sesé reports personal fees and non-financial support from Roche/Genentech (consultant and congress), and non-financial support from Boehringer Ingelheim (congress), outside the submitted work. Conflict of interest: Y. Nguyen has nothing to disclose. Conflict of interest: E. Giroux Leprieur reports grants, personal fees and non-financial support from AstraZeneca, Bristol-Myers-Squibb and Roche, personal fees and non-financial support from Boehringer Ingelheim, MSD and Novartis, and non-financial support from Takeda, outside the submitted work. Conflict of interest: I. Annesi-Maesano has nothing to disclose. Conflict of interest: C. Cavalin has nothing to disclose. Conflict of interest: J. Goupil de Bouillé has nothing to disclose. Conflict of interest: L. Demestier has nothing to disclose. Conflict of interest: R. Dhote has nothing to disclose. Conflict of interest: Y. Tandjaoui-Lambiotte has nothing to disclose. Conflict of interest: A. Bauvois has nothing to disclose. Conflict of interest: M. Pépin has nothing to disclose. Conflict of interest: S. Curac has nothing to disclose. Conflict of interest: S. Beaune has nothing to disclose. Conflict of interest: B. Duchemann reports non-financial support from Roche, Oxyvie, Pfizer and AstraZeneca, and personal fees from MSD, outside the submitted work. Conflict of interest: H. Nunes reports grants and personal fees from Roche/Genentech (consultant and research support fees) and Boehringer Ingelheim (consultant and research support fees), personal fees from Galapagos (expert for clinical endpoint committee), other from Sanofi (investigator of clinical trial), Gilead (investigator of clinical trial), Novartis (investigator of clinical trial) and Galecto Biotech AB (investigator of clinical trial), during the conduct of the study; personal fees from Actelion Pharmaceuticals (board expert for clinical trial), outside the submitted work.

Published
2020
Full Text
View/download PDF

3. Environmental contamination related to SARS-CoV-2 in ICU patients.

Author

Lomont A, Boubaya M, Khamis W, Deslandes A, Cordel H, Seytre D, Alloui C, Malaure C, Bonnet N, Carbonnelle E, Cohen Y, Nunes H, Bouchaud O, Zahar JR, and Tandjaoui-Lambiotte Y

Abstract

Background: The coronavirus disease 2019 (COVID-19) outbreak is a primary global concern, and data are lacking concerning risk of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) environmental contamination., Objective: To identify risk factors for SARS-CoV-2 environmental contamination in COVID-19 patients admitted to the intensive care unit (ICU)., Methods: A prospective single centre 1-day study was carried out in an ICU. Four surfaces (the ventilator control screen, the control buttons of the syringe pump, the bed rails and the computer table located >1 m away from the patient) were systematically swabbed at least 8 h after any cleaning process. We analysed clinical, microbiological and radiological data to identify risk factors for SARS-CoV-2 environmental contamination., Results: 40% of ICU patients were found to contaminate their environment. No particular trend emerged regarding the type of surface contaminated. Modality of oxygen support (high-flow nasal cannula oxygenation, invasive mechanical ventilation, standard oxygen mask) was not associated with the risk of environmental contamination. Univariate analysis showed that lymphopenia <0.7×10 9 ·L -1 was associated with environmental contamination., Conclusion: Despite small sample size, our study generated surprising results. Modality of oxygen support is not associated with risk of environmental contamination. Further studies are needed., Competing Interests: Conflict of interest: A. Lomont has nothing to disclose. Conflict of interest: M. Boubaya has nothing to disclose. Conflict of interest: W. Khamis has nothing to disclose. Conflict of interest: A. Deslandes has nothing to disclose. Conflict of interest: H. Cordel has nothing to disclose. Conflict of interest: D. Seytre has nothing to disclose. Conflict of interest: C. Alloui has nothing to disclose. Conflict of interest: C. Malaure has nothing to disclose. Conflict of interest: N. Bonnet has nothing to disclose. Conflict of interest: E. Carbonnelle has nothing to disclose. Conflict of interest: Y. Cohen has nothing to disclose. Conflict of interest: H. Nunes has nothing to disclose. Conflict of interest: O. Bouchaud has nothing to disclose. Conflict of interest: J-R. Zahar has nothing to disclose. Conflict of interest: Y. Tandjaoui-Lambiotte has nothing to disclose., (Copyright ©ERS 2020.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results